Clinical Trial Detail

NCT ID NCT04408638
Title A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruitment Not yet recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

diffuse large B-cell lymphoma

Therapies

Obinutuzumab

Gemcitabine + Oxaliplatin + Rituximab

Gemcitabine + Oxaliplatin + RO7082859

Age Groups: senior adult

No variant requirements are available.